Sobi Reports Positive Growth in Q1 2025 Financial Results with Strong Performance in Hematology

Sobi's Q1 2025 Financial Performance

On April 29, 2025, Swedish Orphan Biovitrum AB, commonly known as Sobi, published its financial report for the first quarter of 2025. The results indicate a promising trajectory for the company, showcasing a total revenue increase of 3%, amounting to SEK 6,465 million compared to SEK 6,256 million in the same period last year.

Hematology Segment Sees Significant Growth

A key highlight from Sobi's report was the performance of its hematology segment, which recorded a remarkable revenue increase of 13% at constant exchange rates (CER), totaling SEK 4,632 million. This growth was primarily attributed to the successful launch of Altuvoct, which generated SEK 455 million, and strong sales figures for Doptelet and Aspaveli/Empaveli, contributing SEK 1,129 million and SEK 333 million, respectively. However, there was a slight decrease in revenue from Vonjo, which recorded sales of SEK 306 million, down from SEK 320 million.

Immunology Revenue Declines

Conversely, Sobi's immunology segment faced challenges during this quarter, with a 21% decline at CER, resulting in revenues of SEK 1,526 million, down from SEK 1,908 million. This shortfall was mainly influenced by a notable drop in sales of Synagis, which fell to SEK 21 million from SEK 520 million the previous year. Furthermore, royalties from Beyfortus decreased to SEK 189 million, down from SEK 318 million. Despite these setbacks, the strong sales of Gamifant and Kineret provided some balance, achieving SEK 582 million and SEK 735 million, respectively, bolstering the overall performance.

Strategic Portfolio Growth

An encouraging aspect of the report was the significant growth in Sobi's strategic portfolio, which includes key products like Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, and Zynlonta. Revenue from this strategic segment grew an impressive 46% at CER, totaling SEK 3,255 million, significantly up from SEK 2,194 million.

Financial Metrics and Future Outlook

Sobi's adjusted EBITA margin for this quarter was reported at 36%, slightly down from the previous year’s 37%, while the EBITA reached SEK 2,260 million, reflecting a consistent margin of 35%. Earnings per share (EPS) showed positive growth, with pre-dilution EPS rising to SEK 2.55, up from SEK 2.35 in Q1 2024. The adjusted EPS also saw a modest increase, reaching SEK 2.75 from SEK 2.70.

Looking ahead, Sobi maintains its guidance for 2025, projecting a high single-digit percentage revenue increase at constant exchange rates. The company anticipates that its adjusted EBITA margin will remain in the mid-30s percentage range of revenue, indicating a robust framework for sustainable growth.

Conclusion

As Sobi progresses through 2025, the company’s quarterly report illustrates a mixed but primarily positive financial landscape. The strong demand for hematology products, coupled with strategic portfolio expansion, presents a solid foundation for future growth. Investors and analysts are invited to further explore these results in a conference call scheduled for later today, where they can gain additional insights and engage in a Q&A session regarding Sobi's outlook and strategies moving forward.